A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied for nootropic and neuroprotective effects, typically administered intranasally in research.
Mechanism under study
Research associates Semax with increased BDNF and NGF expression, modulation of dopaminergic and serotonergic systems, and neuroprotective activity in ischemia models.
Research-reported dosing
Research references commonly cite ~200–600 mcg intranasally. Most human evidence is from Russian clinical research; it is not FDA-approved.
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
A 300 mcg dose ≈ 6 units (50 mcg per unit).
Open this mix in the calculator →Source research-grade Semax ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Semax FAQ
What is Semax?
A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied for nootropic and neuroprotective effects, typically administered intranasally in research.
What is the half-life of Semax?
Short in plasma; intranasal route is standard in research.
What is the research-reported dosing for Semax?
Research references commonly cite ~200–600 mcg intranasally. Most human evidence is from Russian clinical research; it is not FDA-approved.
How is Semax reconstituted?
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
Is Semax FDA-approved?
Semax has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.